Large Volume Wearable Injectors Market Landscape 2020-2030 – Extensive Focus on the Emergence of Patient-Centric, Convenient, Cost-Effective and User-Friendly Wearable Drug Delivery Solutions

DUBLIN, July 27, 2020 /PRNewswire/ — The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and…

DUBLIN, July 27, 2020 /PRNewswire/ — The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices” report has been added to’s offering.

Research and Markets Logo

This report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next ten years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030.

The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the:

  • [A] type of device (patch pump, injector and infusion pump and injector)
  • [B] usability (reusable and disposable)
  • [C] therapeutic area (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others)
  • [D] key geographies (North America, Europe, Asia Pacific and rest of the world)

Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life. In fact, according to the World Health Organization (WHO), over 50% of the global population is currently estimated to be suffering from at least one chronic disease.

The past few years have witnessed introduction of several innovative pharmaceutical interventions for the treatment of a number of such diseases. However, majority of the available treatment options require parenteral administration of the drug, frequent dosing, and involve repeated hospital visits.

Treatment administration via the parenteral route is also associated with various concerns, such as dosing errors, risk of microbial contamination and needlestick injuries. These are known to be the primary factors affecting medication adherence and, thereby, have a significant impact on therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions (such as autoinjectors, pen injectors, prefilled syringes) to overcome the challenges associated with the administration of both conventional and novel drug/therapy molecules.

In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks/pandemics (such as the one being faced due to the novel corona virus/COVID-19). Amongst modern drug delivery practices, the concept of self-injection has facilitated the administration of medications outside the clinical setting. Such practices also allow reductions in healthcare costs and enable the optimal usage of healthcare resources.

Specifically, large volume wearable injectors used for subcutaneous drug delivery, have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as biologics) in large volumes (more than 1 mL), offering numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, and an almost negligible risk of needlestick injuries. Such devices have captured the interest of several stakeholders in this industry and are being used for the administration of both insulin and non-insulin drugs.

The field is presently witnessing a lot of innovation, such as the development of integrated mobile applications with smart health monitoring, artificial intelligence algorithms and other interesting features (including provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual/audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.

Amongst other elements, the report includes:

  • An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump/injector and infusion pump/injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle/cannula and needle/catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell/expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device/personal diabetes manager (PDM)/smartphone) in the insulin delivery devices.
  • A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems (in case of insulin devices).
  • Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types of deals.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • An in-depth analysis of the various patents that have been submitted/filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority/patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed/granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio).
  • A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).
  • A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years.
  • A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes.
  • A case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Mark Banister (CEO, Medipacs/RxActuator)
  • Michael Hooven (CEO, Enable Injections)
  • Jesper Roested (CEO, Subcuject)
  • Pieter Muntendam (former President and CEO, scPharmaceuticals)
  • Menachem Zucker (VP and Chief Scientist, Elcam Medical)
  • Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)
  • Mindy Katz (Director of Product, Sorrel Medical)

Key Questions Answered

  • Who are the leading large volume wearable device developers?
  • What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of non-insulin drugs?
  • What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of insulin?
  • What are the types of drug candidates that are suited for delivery via large volume wearable injectors?
  • Who are the key contract service providers involved in this domain?
  • What are medical device regulations across different regions?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Large Volume Wearable Injectors: Current Market Landscape

5. Product Competitiveness Analysis

6. Large Volume Wearable Injectors: Key Players

7. Drug-Device Combinations: Tabulated Profiles

8. Partnerships and Collaborations

9. Key Acquisition Targets

10. Patent Analysis

11. Large Volume Wearable Injectors: Likely Drug Candidates

12. Emerging Trends on Social Media

13. Clinical Trial Analysis

14. Case Study: Role of CMOs in Device Development Supply Chain

15. Regulatory and Reimbursement Landscape for Medical Devices

16. Market Sizing and Opportunity Analysis

17. SWOT Analysis

18. Executive Insights

Companies Mentioned

  • 3M
  • Abbott
  • AbbVie
  • AbGenomics
  • Ablynx
  • Acceleron Pharma
  • Accenture
  • Actavis Pharma
  • ADC Therapeutics
  • Adrenomed
  • Aduro Biotech
  • Advaxis
  • Aeglea BioTherapeutics
  • Aetna
  • Affibody
  • Affimed
  • Agenus
  • AgonOx
  • Akesobio Australia
  • Alder BioPharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Alkahest
  • Alkermes
  • Allakos
  • Allergan
  • Alnylam Pharmaceuticals
  • Allozyne
  • AlphaCore Pharma
  • Altor BioScience
  • Ambrx
  • amcure
  • Amgen
  • Amicus Therapeutics
  • Amphivena Therapeutics
  • Amplyx Pharmaceuticals
  • Angiochem
  • Antares Pharma
  • Antaros Medical
  • Apellis Pharmaceuticals
  • Aprea Therapeutics
  • Aptevo Therapeutics
  • argenx
  • Argos Therapeutics
  • ArmaGen
  • ARMO BioSciences
  • Aronora
  • Asante Solutions
  • Ascensia Diabetes Care
  • Asklepion Pharmaceuticals
  • Astorg Partners
  • Astellas Pharma
  • AstraZeneca
  • Atridia
  • Australasian Medical & Scientific
  • Axon Neuroscience
  • Baril
  • Basilea Pharmaceutica
  • Bastian Solutions
  • Battelle
  • Baxter International
  • Bayer
  • Bayhill Therapeutics
  • Becton Dickinson
  • BeiGene
  • Beijing Dongfang Biotech
  • Bespak
  • Beta Bionics
  • Bigfoot Biomedical
  • BioArctic
  • Biogen
  • BioIntegrator
  • Bioject Medical Technologies
  • BioMarin Pharmaceutical
  • Bioniz Therapeutics
  • BioNTech
  • Bio-Path Holdings
  • Biotest Pharmaceuticals
  • Bio-Thera Solutions
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bristol Myers Squibb
  • Bhler Motor
  • Calando Pharmaceuticals
  • Calibra Medical
  • Cam Med
  • CANbridge Life Sciences
  • Cancer Advances
  • Cara Therapeutics
  • Cardiome Pharma
  • Care Innovations
  • Catalyst Biosciences
  • Celgene
  • Celldex Therapeutics
  • CeQur
  • Chimerix
  • CHO Pharma
  • Chugai Pharmaceutical
  • Cleveland BioLabs
  • Conjupro Biotherapeutics
  • Consort Medical
  • ContraFect
  • ConvaTec
  • Cordant Group
  • Cour Pharmaceutical Development
  • CSL Behring
  • CStone Pharmaceuticals
  • CureTech
  • CytoDyn
  • Daikyo Seiko
  • Datwyler
  • Debiotech
  • DEKA
  • Dekkun
  • Delta-Fly Pharma
  • Dendreon
  • Dexcom
  • Diabeloop
  • DiaMedica Therapeutics
  • Diamyd Medical
  • DreaMed Diabetes
  • Duke University
  • E3D Elcam Drug Delivery Devices
  • European Connected Health Alliance (ECHAlliance)
  • Eisai
  • Eitan Group
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Emergent BioSolutions
  • Enable Injections
  • Endocyte
  • EnGeneIC
  • EOFlow
  • EpicentRx
  • Eris Lifesciences
  • EVER Pharma
  • Evidation Health
  • F2G
  • Fabrico
  • Ferring Pharmaceuticals
  • FibroGen
  • Fitbit
  • Five Prime Therapeutics
  • Flex Pharma
  • Flex
  • Flowonix Medical
  • Fresenius Medical Care
  • Galaxy Biotech
  • Galena Biopharma
  • FedEx Supply Chain
  • Genentech
  • GeneScience Pharmaceuticals
  • Genexine
  • Genzyme
  • Georgia Institute of Technology
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Gliknik
  • Glooko
  • Guangzhou Cellprotek Pharmaceutical
  • HAL Allergy
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Harvard Pilgrim Health Care
  • Haselmeier
  • HealthPrize Technologies
  • Helsinn Healthcare
  • Hemispherx Biopharm
  • Hoffmann-La Roche
  • Huabo Biopharm
  • IBM Watson
  • International Diabetes Federation
  • ImClone Systems
  • Immatics Biotechnologies
  • Immune Response BioPharma
  • ImmunGene
  • Immunocore
  • ImmunoFrontier
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immunovaccine
  • Implicit Bioscience
  • Incuron
  • Incyte
  • Innate Pharma
  • Innovent Biologics
  • Inovio Pharmaceuticals
  • Insulet
  • iNtRON Biotechnology
  • IO Biotech
  • Ionis Pharmaceuticals
  • Ipsen
  • iSense CGM
  • Janssen
  • Jerini
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Jiangsu T-Mab Biopharma
  • Johnson & Johnson
  • Jounce Therapeutics
  • Juvenile Diabetes Research Foundation
  • KaloBios Pharmaceuticals
  • Kiniksa Pharmaceuticals
  • Kissei Pharmaceutical
  • Klue
  • Kura Oncology
  • Kyowa Hakko Kirin
  • Labrys Biologics
  • LEO Pharma
  • Levicept
  • Life Science Pharmaceuticals
  • MabVax Therapeutics
  • MacroGenics
  • Massachusetts Institute of Technology
  • MedImmune
  • Medimop Medical Projects
  • Medipacs
  • Medtronic
  • Medtrum Technologies
  • Menarini Diagnostics
  • Menarini Group
  • Merck
  • Merck Sharp & Dohme
  • Mercy Technology Services
  • Mereo BioPharma
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Merz Pharma
  • Millennium Pharmaceuticals
  • MiNA Therapeutics
  • miRagen Therapeutics
  • Mitsubishi Tanabe Pharma
  • Mode AGC (Automated Glucose Control)
  • Moderna Therapeutics
  • Molecular Partners
  • Molecular Templates
  • MolMed
  • Montagu Private Equity
  • MorphoSys
  • Morphotek
  • Movi
  • MTD Micro Molding
  • mySugr
  • NanoPass Technologies
  • NantBioScience
  • Naurex
  • Navidea Biopharmaceuticals
  • Nemera
  • Neogenix Oncology
  • Neon Therapeutics
  • NeuroDerm
  • New Zealand Medical & Scientific
  • Noble
  • Nordic Bioscience
  • Nordic Infucare
  • Northern Biologics
  • Novartis Pharmaceuticals
  • Novimmune
  • NOVO Engineering
  • Novo Nordisk
  • OBI Pharma
  • Octapharma
  • Omeros
  • Oncology Venture
  • OncoMed Pharmaceuticals
  • OncoPep
  • Oncopeptides
  • Oncternal Therapeutics
  • Oncurious
  • Opthea
  • Optimer Pharmaceuticals
  • OSE Immunotherapeutics
  • Otsuka Pharmaceutical
  • Owen Mumford
  • Paion UK
  • Panacea Biotec
  • PercuSense
  • Pfizer
  • PharmaJet
  • PharmaMar
  • PharmaSens
  • PhaseBio Pharmaceuticals
  • Phillips-Medisize
  • Philogen
  • Phosplatin Therapeutics
  • Pierre Fabre
  • Pique Therapeutics
  • Polaris Group
  • Polyphor
  • Prescient Therapeutics
  • Prestige BioPharma
  • Promedior
  • Prometheus Laboratories
  • Protalix Biotherapeutics
  • Proven Process Medical Devices
  • Pulmonary Hypertension Association
  • Qualcomm
  • Quest PharmaTech
  • Quintessence Biosciences
  • Ratio Drug Delivery
  • Recro Pharma
  • Recipharm
  • Regeneron Pharmaceuticals
  • REM Systems
  • REMD Biotherapeutics
  • Resolve Therapeutics
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Roche
  • Roehr pharmaceuticals
  • R-Pharm
  • Rubin Medical
  • RxActuator
  • Sagentia
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Santarus
  • Saol Therapeutics
  • Savient Pharmaceuticals
  • scPharmaceuticals
  • Seattle Genetics
  • Selecta Biosciences
  • Selexys Pharmaceuticals
  • Sensile Medical
  • Serina Therapeutics
  • SFC Fluidics
  • Shire
  • SHL Medical
  • Singularity University
  • SMC Global
  • Smiths Medical
  • Sonceboz
  • SOOIL Development
  • SPARK Strategic Ideas
  • SQ Innovation
  • SteadyMed Therapeutics
  • Stealth BioTherapeutics
  • Stemline Therapeutics
  • Stevanato Group
  • Subcuject
  • Sumitomo Dainippon Pharma
  • Sunovion Pharmaceuticals
  • Swissfillon
  • SymBio Pharmaceuticals
  • Symphogen
  • Synectics
  • Synermore Biologics
  • Syntimmune
  • Syros Pharmaceuticals
  • TaiMed Biologics
  • Taiwan Liposome Company
  • Takeda Pharmaceutical
  • Tandem Diabetes Care
  • Tanvex BioPharma
  • Tarveda Therapeutics
  • Teva Pharmaceutical
  • TG Therapeutics
  • Theras Lifetech
  • Tidepool
  • Tolero Pharmaceuticals
  • TRACON Pharmaceuticals
  • Translational Sciences
  • Turnstone Biologics
  • Tyndall National Institute
  • TypeZero Technologies
  • Union Chimique Belge (UCB)
  • United BioPharma
  • United Therapeutics
  • University of Arizona
  • University of Bern
  • University of Colorado
  • University of Hertfordshire
  • University of Virginia
  • Vaccinex
  • Vaccinogen
  • Valtronic
  • vasopharm BIOTECH
  • Verily Life Sciences
  • Vetter Pharma
  • ViCentra
  • ViiV Healthcare
  • Visterra
  • Vivozon
  • Weibel CDS
  • West Pharmaceutical Services
  • Wockhardt
  • XBiotech
  • Xencor
  • XOMA
  • Ypsomed
  • Zafgen
  • Zealand Pharma
  • Zollner
  • Zuellig Pharma

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Cision View original content:—extensive-focus-on-the-emergence-of-patient-centric-convenient-cost-effective-and-user-friendly-wearable-drug-delivery-solutions-301100257.html

SOURCE Research and Markets